FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer

References

• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–12. doi:10.1001/jama.2021.0106.
   PubMed Web of Science ®Google Scholar
• Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18:18.
   Web of Science ®Google Scholar
• Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17:3837–3849.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442. doi:10.3389/fimmu.2022.964442.
   PubMedGoogle Scholar
• Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–674.
   PubMed Web of Science ®Google Scholar
• Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. doi:10.1186/s12943-021-01489-2.
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches. J Natl Cancer Inst. 2019;111:1131–1141.
   PubMedGoogle Scholar
• Wang Y-D, Chen W-D, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008;18:1087–1095.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem. 2003;278:104–110.
   PubMed Web of Science ®Google Scholar
• Massafra V, Milona A, Vos HR, Ramos RJJ, Gerrits J, Willemsen ECL, Ramos Pittol JM, Ijssennagger N, Houweling M, Prinsen HCMT. Farnesoid X receptor activation promotes hepatic amino acid catabolism and ammonium clearance in mice. Gastroenterology. 2017;152(6):152. doi:10.1053/j.gastro.2017.01.014.
   Web of Science ®Google Scholar
• Peng X, Wu W, Zhu B, Sun Z, Ji L, Ruan Y, Zhou M, Zhou L, Gu J. Activation of farnesoid X receptor induces RECK expression in mouse liver. Biochem Biophys Res Commun. 2014;443:211–216.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang X, Lu Y, Meng S, Quan H, Hou P, Tong P, Chai D, Gao X, Zheng J. The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines. Cell Death Disease. 2020;11:31.
   PubMed Web of Science ®Google Scholar
• Dai J, Wang H, Shi Y, Dong Y, Zhang Y, Wang J. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol. 2011;4:41.
   PubMed Web of Science ®Google Scholar
• De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ, Dufour J-F. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci. 2004;49(6):982–989. doi:10.1023/B:DDAS.0000034558.78747.98.
   PubMed Web of Science ®Google Scholar
• You W, Chen B, Liu X, Xue S, Qin H, Jiang H. Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. null. 2017;7(1):591. doi:10.1038/s41598-017-00698-4.
   Google Scholar
• Lee JY, Lee KT, Lee JK, Lee KH, Jang KT, Heo JS, Choi SH, Kim Y, Rhee JC. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br J Cancer. 2011;104(6):1027–1037.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Tsoukalas N, Alexandrou P, Tsourouflis G, Dana E, Delladetsima I, Patsouris E, Theocharis S. Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol. 2017;13:1785–1792.
   PubMed Web of Science ®Google Scholar
• Torres J, Bao X, Iuga AC, Chen A, Harpaz N, Ullman T, Cohen BL, Pineton de Chambrun G, Asciutti S, Odin JA. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis. 2013;19(2):275–282.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, Shao T, Song Q, Zhu F, Zhang L. Probiotic lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatology (Baltimore, Md). 2020;71(6):2050–2066. doi:10.1002/hep.30975.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Gayer CP. The pathophysiology of Farnesoid X receptor (FXR) in the GI tract: inflammation, barrier function and innate immunity. Cells. 2021;10:10.
   Web of Science ®Google Scholar
• Wang L, Xu X, Shang B, Sun J, Liang B, Wang X, You W, Jiang S. High farnesoid X receptor expression predicts favorable clinical outcomes in PDL1(low/negative) nonsmall cell lung cancer patients receiving antiPd1based chemoimmunotherapy. Int J Oncol. 2022;60:60.
   PubMed Web of Science ®Google Scholar
• You W, Li L, Sun D, Liu X, Xia Z, Xue S, Chen B, Qin H, Ai J, Jiang H. Farnesoid X receptor constructs an immunosuppressive microenvironment and sensitizes FXRPD-L1 NSCLC to anti-PD-1 immunotherapy. Cancer Immunol Res. 2019;7:990–1000.
   PubMed Web of Science ®Google Scholar
• Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A, Berger A, Trauner M. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer. 2012;130:2232–2239.
   PubMed Web of Science ®Google Scholar
• Yu J, Li S, Guo J, Xu Z, Zheng J, Sun X. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis. Cell Death Disease. 2020;11:640.
   PubMed Web of Science ®Google Scholar
• Guo S, Peng Y, Lou Y, Cao L, Liu J, Lin N, Cai S, Kang Y, Zeng S, Yu L. Downregulation of the farnesoid X receptor promotes colorectal tumorigenesis by facilitating enterotoxigenic bacteroides fragilis colonization. Pharmacol Res. 2022;177:106101.
   PubMed Web of Science ®Google Scholar
• Yu J, Yang K, Zheng J, Zhao P, Xia J, Sun X, Zhao W. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell Death & Disease. 2022;13:388.
   PubMed Web of Science ®Google Scholar
• Li S, Xu Z, Guo J, Zheng J, Sun X, Yu J. Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene. J Cell Mol Med. 2020;24:14549–14560.
   PubMed Web of Science ®Google Scholar
• Gong Y, Li K, Qin Y, Zeng K, Liu J, Huang S, Chen Y, Yu H, Liu W, Ye L. Norcholic acid promotes tumor progression and immune escape by regulating Farnesoid X receptor in hepatocellular carcinoma. Front Oncol. 2021;11:711448.
   PubMedGoogle Scholar
• Hotta M, Sakatani T, Ishino K, Wada R, Kudo M, Yokoyama Y, Yamada T, Yoshida H, Naito Z. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5. Biochem Biophys Res Commun. 2019;519:824–831.
   PubMed Web of Science ®Google Scholar
• Barone I, Vircillo V, Giordano C, Gelsomino L, Gyorffy B, Tarallo R, Rinaldi A, Bruno G, Caruso A, Romeo F. Activation of farnesoid X receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts. Cancer Lett. 2018;437:89–99.
   PubMed Web of Science ®Google Scholar
• Guo J, Zheng J, Mu M, Chen Z, Xu Z, Zhao C, Yang K, Qin X, Sun X, Yu J. GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis. Biochem Biophys Res Commun. 2021;548:60–66.
   PubMed Web of Science ®Google Scholar
• Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–362.
   PubMed Web of Science ®Google Scholar
• Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–693.
   PubMed Web of Science ®Google Scholar
• Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett. 2010;287:123–135.
   PubMed Web of Science ®Google Scholar
• Joo JH, Liao G, Collins JB, Grissom SF, Jetten AM. Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res. 2007;67:7929–7936.
   PubMed Web of Science ®Google Scholar
• King AP, Wilson JJ. Endoplasmic reticulum stress: an arising target for metal-based anticancer agents. Chem Soc Rev. 2020;49:8113–8136.
   PubMed Web of Science ®Google Scholar
• Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67:863–867.
   PubMed Web of Science ®Google Scholar
• Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, Ganapathy V, Gonzalez FJ. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. null. 2009;328:469–477.
   Google Scholar
• Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78:1019–1033.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487–500.
   PubMed Web of Science ®Google Scholar
• Alawad AS, Levy C. FXR agonists: from bench to bedside, a guide for clinicians. Dig Dis Sci. 2016;61:3395–3404.
   PubMed Web of Science ®Google Scholar